GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 30+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of in-silico drug discovery.

"Generative AI in Drug Discovery Market Size" reflects the size of the generative artificial intelligence (GAI) market in drug discovery. GII is an advanced technology that uses generation algorithms to generate new molecules and potential drug candidates.

Leading clinical AI companies are using advanced AI technologies to accelerate and streamline their research processes, helping to reduce the time and cost of developing new drugs and medical technologies.

Taken together, the top 10 companies are set to represent just over a third of all sales in a global medtech market that is expected to reach nearly $595 billion in sales in 2024—again, little change compared to Evaluate’s analysis of 2017.

Tech-first companies lead AI drug discovery, utilizing advanced technologies and AI algorithms to expedite the identification of drug candidates, predict interactions, and optimize designs. They aim to reduce costs and bring safer, more effective treatments to patients, revolutionizing the pharmaceutical industry.

Medtech businesses are becoming stand-alone companies. That translates into new names among 2022’s Medtech Big 100 ranking of the world’s largest medical device companies.

Artificial Intelligence, or AI, is at the forefront of innovation in healthcare. It has infiltrated healthcare tremendously in the last decade, bringing billions of dollars to different sectors. Top AI applications in healthcare include robot-assisted surgery, virtual nursing assistants, dosage error reduction, and much more. These applications are projected to create$150 bn in annual savings for the healthcare economy by 2026.

Artificial intelligence (AI) continues to play a significant role in addressing many of the core challenges currently faced by the pharmaceutical industry.

The top 10 AI-enabled pharmaceutical companies are leading the industry by using cutting-edge technology to improve and streamline every step of the drug development process.

Here is a list of more established companies, bringing the power of next-gen predictive and generative AI tools to the field of clinical and translational research (in alphabetic order):

The Medtech Big 100 includes annual revenue, R&D spending, headcount, CEOs and key leaders, headquarters locations and descriptions of each company. Typically, we gather the data from regulatory disclosures filed with the U.S. Securities and Exchange Commission. Some companies, such as privately held firms, share data directly with us.